Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.31 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28024572 | 0.90 | KDM4E (0.34) | KDM4EALDH1A1JAK2JAK1TYK2 | |
| SCHEMBL12385860 | 0.89 | KDM4E (0.39) | KDM4EALDH1A1JAK2JAK1TYK2 | |
| SCHEMBL15014588 | 0.89 | KDM4E (0.39) | KDM4EALDH1A1JAK2JAK1TYK2 | |
| SCHEMBL20096220 | 0.88 | HRH3 (0.44) | L3MBTL3HRH3KDM2BMGLL | |
| SCHEMBL10645949 | 0.86 | IRAK4 (0.35) | KDM4EALDH1A1JAK2JAK1TYK2 | |
| SCHEMBL10645954 | 0.86 | IRAK4 (0.35) | KDM4EALDH1A1JAK2JAK1TYK2 | |
| SCHEMBL153765 | 0.85 | L3MBTL3 (0.39) | KDM4EALDH1A1L3MBTL3KDM2BCYP2D6 | |
| SCHEMBL27855229 | 0.85 | L3MBTL3 (0.36) | KDM4EALDH1A1JAK2JAK1TYK2 | |
| SCHEMBL10986045 | 0.84 | KDM4E (0.38) | KDM4EALDH1A1JAK2JAK1TYK2 | |
| SCHEMBL4594209 | 0.84 | JAK2 (0.34) | KDM4EALDH1A1JAK2JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9636335-B2 | Heteroaryl compounds as 5-HT4 receptor ligands | SUVEN LIFE SCIENCES LIMITED (IN) | 2017-05-02 | — | — | US | disclosed |
| CN-103380131-B | As the heteroaryl compound of 5-HT4 receptors ligand | SUVEN LIFE SCIENCES LTD. (IN) | 2015-12-02 | — | — | CN | disclosed |
| US-20150283125-A1 | HETEROARYL COMPOUNDS AS 5-HT4 RECEPTOR LIGANDS | SUVEN LIFE SCIENCES LTD (IN) | 2015-10-08 | — | — | US | disclosed |
| US-9079894-B2 | Heteroaryl compounds as 5-HT4 receptor ligands | SUVEN LIFE SCIENCES LTD (IN) | 2015-07-14 | — | — | US | disclosed |
| EP-2758394-B1 | HETEROARYL COMPOUNDS AS 5-HT4 RECEPTOR LIGANDS | SUVEN LIFE SCIENCES LTD (IN) | 2015-02-18 | — | — | EP | disclosed |
| EP-2758394-A1 | HETEROARYL COMPOUNDS AS 5-HT4 RECEPTOR LIGANDS | Suven Life Sciences Limited (IN) | 2014-07-30 | — | — | EP | disclosed |
| US-20140187581-A1 | HETEROARYL COMPOUNDS AS 5-HT4 RECEPTOR LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2014-07-03 | — | — | US | disclosed |
| CN-103380131-A | Heteroaryl compounds as 5-ht4 receptor ligands | SUVEN LIFE SCIENCES LTD | 2013-10-30 | — | — | CN | disclosed |
| CN-101932577-B | Heteroaryl-substituted piperidines | BAYER HEALTHCARE AG | 2013-07-17 | — | — | CN | disclosed |
| WO-2013042135-A1 | HETEROARYL COMPOUNDS AS 5-HT4 RECEPTOR LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2013-03-28 | — | — | WO | disclosed |
| WO-2009068214-A2 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-06-04 | — | — | WO | disclosed |
| US-20080113995-A1 | 1-Cyclopentyl-4-{2-[5-(4-methanesulfonylphenyl)[1,2,4]oxadiazol-3-yl]ethyl}piperidine; histamine-H3 receptor antagonist or inverse agonist; nervous system, cardiovascular , respiratory system, gastrointestinal system and endocrinological system disorders | NOVO NORDISK A/S (DK) | 2008-05-15 | — | — | US | disclosed |
| US-20080113995-A1 | 1-Cyclopentyl-4-{2-[5-(4-methanesulfonylphenyl)[1,2,4]oxadiazol-3-yl]ethyl}piperidine; histamine-H3 receptor antagonist or inverse agonist; nervous system, cardiovascular , respiratory system, gastrointestinal system and endocrinological system disorders | NOVO NORDISK A/S (DK) | 2008-05-15 | — | — | US | disclosed |
| US-20080113995-A1 | 1-Cyclopentyl-4-{2-[5-(4-methanesulfonylphenyl)[1,2,4]oxadiazol-3-yl]ethyl}piperidine; histamine-H3 receptor antagonist or inverse agonist; nervous system, cardiovascular , respiratory system, gastrointestinal system and endocrinological system disorders | NOVO NORDISK A/S (DK) | 2008-05-15 | — | — | US | disclosed |
| US-7332508-B2 | heterocyclic amines such as 1-Cyclopentyl-4-{2-[5-(4-methanesulfonylphenyl)[1,2,4]oxadiazol-3-yl]ethyl}piperidine and salts, used as histamine-H3 receptor antagonists for treatment of nervous system, cardiovascular , respiratory system, gastrointestinal system and endocrinological system disorders | NOVO NORDISK A/S (DK) | 2008-02-19 | — | — | US | disclosed |
| US-7332508-B2 | heterocyclic amines such as 1-Cyclopentyl-4-{2-[5-(4-methanesulfonylphenyl)[1,2,4]oxadiazol-3-yl]ethyl}piperidine and salts, used as histamine-H3 receptor antagonists for treatment of nervous system, cardiovascular , respiratory system, gastrointestinal system and endocrinological system disorders | NOVO NORDISK A/S (DK) | 2008-02-19 | — | — | US | disclosed |
| US-7332508-B2 | heterocyclic amines such as 1-Cyclopentyl-4-{2-[5-(4-methanesulfonylphenyl)[1,2,4]oxadiazol-3-yl]ethyl}piperidine and salts, used as histamine-H3 receptor antagonists for treatment of nervous system, cardiovascular , respiratory system, gastrointestinal system and endocrinological system disorders | NOVO NORDISK A/S (DK) | 2008-02-19 | — | — | US | disclosed |
| EP-1585515-A2 | PIPERIDINE AND PYRROLIDINE DERIVATIVES AS ANTAGONISTS OF HISTAMINE H3 RECEPTOR | NOVO NORDISK A/S (DK) | 2005-10-19 | — | — | EP | disclosed |
| US-20050107434-A1 | heterocyclic amines such as 1-Cyclopentyl-4-{2-[5-(4-methanesulfonylphenyl)[1,2,4]oxadiazol-3-yl]ethyl}piperidine and salts, used as histamine-H3 receptor antagonists for treatment of nervous system, cardiovascular , respiratory system, gastrointestinal system and endocrinological system disorders | VTVX HOLDINGS II LLC | 2005-05-19 | — | — | US | disclosed |
| WO-2004054973-A2 | PIPERIDINE AND PYRROLIDINE DERIVATIVES AS ANTAGONISTS OF HISTAMINE H3 RECEPTOR | NOVO NORDISK A/S (DK) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150283125-A1 | HETEROARYL COMPOUNDS AS 5-HT4 RECEPTOR LIGANDS | HTR4, HTR5A, HTR2C | KDM4E 2298/4885ALDH1A1 921/4885JAK2 872/4885 |
| US-20080113995-A1 | 1-Cyclopentyl-4-{2-[5-(4-methanesulfonylphenyl)[1,2,4]oxadiazol-3-yl]ethyl}piperidine; histamine-H3 receptor antagonist or inverse agonist; nervous system, cardiovascular , respiratory system, gastrointestinal system and endocrinological system disorders | HRH3, HRH4, HRH2 | KDM4E 1219/4885ALDH1A1 2259/4885JAK2 427/4885 |
| US-20140187581-A1 | HETEROARYL COMPOUNDS AS 5-HT4 RECEPTOR LIGANDS | HTR4, HTR5A, HTR2C | KDM4E 2298/4885ALDH1A1 921/4885JAK2 872/4885 |
| US-20050107434-A1 | heterocyclic amines such as 1-Cyclopentyl-4-{2-[5-(4-methanesulfonylphenyl)[1,2,4]oxadiazol-3-yl]ethyl}piperidine and salts, used as histamine-H3 receptor antagonists for treatment of nervous system, cardiovascular , respiratory system, gastrointestinal system and endocrinological system disorders | HRH4, HRH3, HRH2 | KDM4E 854/4885ALDH1A1 1617/4885JAK2 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.